All In Biotech

Drug Trial Radar · NCT01114529

Efficacy, Safety and Evolution of Cardiovascular Parameters in Renal Transplant Recipients

A 24-month, Multi-center, Open-label, Randomized, Controlled Trial to Investigate Efficacy, Safety and Evolution of Cardiovascular Parameters in de Novo Renal Transplant Recipients After Early Calcineurin Inhibitor to Everolimus Conversion

Last checked: Nov 20, 2026Latest source record: May 30, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 828 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

828

Actual

Start

Aug 9, 2010

Primary completion

Oct 30, 2014

Study completion Oct 30, 2014

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
May 3, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to determine whether an early Calcineurin Inhibitor (CNI) to everolimus conversion at 10-14 weeks post transplantation improves renal allograft function without compromising efficacy compared to standard CNI treatment in de novo renal allograft recipients. In addition, the study was designed to evaluate the impact of a CNI-free regimen on evolution of cardiovascular parameters in de novo renal allograft recipients

Conditions

  • Kidney Transplantation

Interventions

  • EverolimusDrug

    Early CNI to everolimus conversion

  • Prograf or NeoralDrug

    Active CNI-based control (Prograf or Neoral)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Estimated Glomerular Filtration Rate (eGFR)Time frame: Month 12

Locations

77 sites in 21 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Córdoba, Argentina

  • Novartis Investigative Site

    Córdoba, Argentina

  • Novartis Investigative Site

    Córdoba, Argentina

  • Novartis Investigative Site

    Santa Fe, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    San Martín, Buenos Aires, Argentina

  • Novartis Investigative Site

    Resistencia, Chaco Province, Argentina

  • Novartis Investigative Site

    Camperdown, New South Wales, Australia

  • Novartis Investigative Site

    Adelaide, South Australia, Australia

  • Novartis Investigative Site

    Clayton, Victoria, Australia

  • Novartis Investigative Site

    Melbourne, Victoria, Australia

  • Novartis Investigative Site

    Linz, Austria

  • Novartis Investigative Site

    Linz, Austria

  • Novartis Investigative Site

    Vienna, Austria

  • Novartis Investigative Site

    Leuven, Belgium

  • Novartis Investigative Site

    Tartu, Estonia

  • Novartis Investigative Site

    Brest, France

  • Novartis Investigative Site

    Nice, France

  • Novartis Investigative Site

    Toulouse, France

  • Novartis Investigative Site

    Tours, France

  • Novartis Investigative Site

    Vandœuvre-lès-Nancy, France

  • Novartis Investigative Site

    Aachen, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Essen, Germany

  • Novartis Investigative Site

    Frankfurt am Main, Germany

  • Novartis Investigative Site

    Hamburg, Germany

  • Novartis Investigative Site

    Hannover Muenden, Germany

  • Novartis Investigative Site

    Heidelberg, Germany

  • Novartis Investigative Site

    Münster, Germany

  • Novartis Investigative Site

    Athens, Greece

  • Novartis Investigative Site

    Athens, Greece

  • Novartis Investigative Site

    Pátrai, Greece, Greece

  • Novartis Investigative Site

    New Delhi, India

  • Novartis Investigative Site

    Visakhapatnam, Andhra Pradesh, India

  • Novartis Investigative Site

    Bangalore, Karnataka, India

  • Novartis Investigative Site

    New Delhi, National Capital Territory of Delhi, India

  • Novartis Investigative Site

    Lucknow, Uttar Pradesh, India

  • Novartis Investigative Site

    Bologna, BO, Italy

  • Novartis Investigative Site

    Padova, PD, Italy

  • Novartis Investigative Site

    Roma, RM, Italy

Showing 40 of 77 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.